+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market - Global Forecast 2026-2032- Product Image
Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6148626
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market is projected to reach USD 1.06 Billion in 2026. It is expected to continue growing at a CAGR of 5.50%, reaching USD 1.46 Billion by 2032.

Radioisotopes Enable More Precise Nuclear Medicine Diagnosis and Treatment

Radioisotopes underpin nuclear medicine procedures that visualize physiological function and deliver targeted radiation to diseased tissue. Diagnostic applications primarily use radiotracers for positron emission tomography and single-photon emission computed tomography, while therapeutic applications use radionuclides to selectively irradiate tumors and other conditions. The field is shaped by clinical evidence, isotope availability, radiopharmaceutical manufacturing, regulatory controls, radiation safety, specialized workforce capacity, and reliable distribution within short product half-lives.

Theranostics, Supply Resilience, and Personalized Care Are Reshaping Adoption

Nuclear medicine is shifting from imaging alone toward integrated diagnostic-and-therapeutic pathways, particularly where a biomarker can identify patients likely to benefit from a matching radionuclide treatment. This transition increases the importance of validated companion imaging, dosimetry, patient selection, and multidisciplinary care. At the same time, reactor maintenance, cyclotron access, target-material availability, transport constraints, and production concentration have highlighted the need for diversified supply chains, contingency planning, and domestic or regional manufacturing capabilities.

Artificial Intelligence Improves Workflow, Quantification, and Treatment Planning

Artificial intelligence is being applied to image reconstruction, denoising, lesion detection, segmentation, classification, quantitative biomarker extraction, and workflow prioritization. In therapy, algorithms can support dosimetry, response assessment, and treatment planning, but their clinical value depends on representative datasets, standardized acquisition protocols, external validation, cybersecurity, and transparent oversight. AI is therefore most useful as a decision-support layer that complements specialist judgment rather than replacing radiologists, nuclear medicine physicians, medical physicists, pharmacists, or technologists.

Regional Readiness Depends on Infrastructure, Regulation, and Isotope Logistics

North America combines advanced clinical infrastructure, substantial research activity, and established radiopharmaceutical capabilities, while continuing to address workforce and supply continuity. Europe benefits from strong academic networks and coordinated regulatory experience, although national reimbursement and production arrangements differ. Asia-Pacific includes highly developed nuclear medicine systems alongside rapidly expanding capabilities, with access, manufacturing, and training varying widely. Latin America is strengthening specialist capacity and referral networks but faces uneven equipment availability and import dependence. The Middle East is investing in advanced oncology and diagnostic services, with logistics and workforce development remaining important. Africa has significant unmet clinical need and opportunities for capacity building, but limited facilities, isotope access, maintenance support, and specialist training constrain broader deployment.

International Alliances Shape Standards, Procurement, and Clinical Collaboration

ASEAN cooperation can support shared training, referral pathways, and regional approaches to isotope access, while BRICS collaboration may encourage research, manufacturing, and technology transfer across diverse health systems. The European Union provides a framework for cross-border regulatory coordination, scientific collaboration, and supply-chain resilience. G7 members contribute substantial research, regulatory, and clinical expertise, and NATO-related capabilities can reinforce emergency preparedness, transport coordination, and radiation-protection standards where relevant. GCC countries are expanding specialized healthcare infrastructure and can benefit from coordinated procurement, workforce development, and regional referral networks.

Country Capabilities Vary Across Production, Clinical Access, and Research Strength

Australia has established nuclear medicine expertise and research capacity, while Brazil and Mexico are important Latin American hubs with continuing needs in regional access and isotope logistics. Canada and the United States combine advanced clinical research, manufacturing, and specialized treatment capabilities. China and India are expanding domestic production, clinical infrastructure, and workforce development, although access is uneven across provinces and states. Japan and South Korea maintain sophisticated imaging and oncology systems. In Europe, France, Germany, Italy, Spain, and the United Kingdom have strong clinical and scientific bases, with differences in reimbursement, procurement, and regulatory implementation. Russia retains nuclear-sector capabilities, while sanctions, trade restrictions, and international cooperation conditions can affect equipment, materials, and collaboration.

Leaders Should Build Resilient, Evidence-Based Nuclear Medicine Ecosystems

Industry leaders should diversify isotope sourcing, establish validated contingency routes, and invest in production, processing, quality control, and specialized transport. They should align diagnostic and therapeutic development around clearly defined patient pathways, generate comparative clinical evidence, and integrate dosimetry and long-term safety monitoring early. Partnerships with hospitals, regulators, academic centers, and professional societies can improve training and adoption. Digital investments should prioritize interoperable systems, standardized data, explainable AI, cybersecurity, and measurable workflow outcomes. Access strategies should include tiered service models, regional referral networks, equipment maintenance, and workforce programs suited to local constraints.

Methodology Integrates Verified Clinical, Policy, Infrastructure, and Supply-Chain Evidence

This executive summary uses a structured review of authoritative public evidence relevant to radioisotopes for nuclear medicine diagnosis and treatment. The assessment considers clinical practice, radiopharmaceutical development, isotope production and distribution, regulatory and radiation-safety requirements, healthcare infrastructure, workforce capacity, regional cooperation, and digital technology. Findings are synthesized comparatively across the specified regions, groups, and countries. Claims are limited to established or clearly documented qualitative patterns; market estimates, market shares, forecasts, and unsupported company-specific assertions are excluded.

Sustainable Progress Requires Clinical Evidence, Reliable Isotopes, and Equitable Access

Radioisotopes remain central to functional diagnosis and targeted treatment, with theranostics increasing the need for coordinated imaging, therapy, dosimetry, and follow-up. The strongest systems will combine resilient supply chains, rigorous regulation, skilled multidisciplinary teams, validated digital tools, and practical access pathways. Progress across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific will depend not only on technological advances but also on sustained investment in production, infrastructure, training, evidence generation, and cross-border cooperation.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Production Method
7.1. Introduction
7.2. Cyclotron Produced
7.3. Generator Produced
7.4. Reactor Produced
8. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Isotope Type
8.1. Introduction
8.2. Fluorine 18
8.3. Gallium 68
8.4. Iodine 131
8.5. Lutetium 177
8.6. Technetium 99M
9. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Radiopharmaceutical Form
9.1. Introduction
9.2. Kit
9.3. Ready To Use
10. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Application
10.1. Introduction
10.2. Diagnostic
10.2.1. Cardiology
10.2.2. Neurology
10.2.3. Oncology
10.3. Therapeutic
11. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by End User
11.1. Introduction
11.2. Diagnostic Center
11.3. Hospital
11.4. Research Institute
12. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Advanced Accelerator Applications S.A.
16.2. Australian Nuclear Science & Technology Organisation
16.3. Bayer AG
16.4. Cardinal Health, Inc.
16.5. Curium Pharma SAS
16.6. Eckert & Ziegler AG
16.7. GE HealthCare Technologies, Inc.
16.8. IRE NV
16.9. Isotopia Molecular Imaging Ltd.
16.10. Jubilant Radiopharma Pvt. Ltd.
16.11. Lantheus Medical Imaging, Inc.
16.12. Nordion Inc.
16.13. NorthStar Medical Radioisotopes LLC
16.14. NTP Radioisotopes Pvt. Ltd.
16.15. Siemens Healthineers AG
16.16. Telix Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, Years Considered for the Study
FIGURE 2. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, Research Design
FIGURE 3. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, Research Framework
FIGURE 4. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, Data Triangulation
FIGURE 5. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2025 vs 2032 (%)
FIGURE 7. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2025 vs 2032 (%)
FIGURE 9. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2025 vs 2032 (%)
FIGURE 11. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Segmentation & Coverage
TABLE 2. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 4. Global Cyclotron Produced Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cyclotron Produced Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cyclotron Produced Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generator Produced Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generator Produced Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generator Produced Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Reactor Produced Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Reactor Produced Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Reactor Produced Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 14. Global Fluorine 18 Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Fluorine 18 Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Fluorine 18 Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Gallium 68 Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Gallium 68 Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Gallium 68 Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Iodine 131 Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Iodine 131 Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Iodine 131 Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Lutetium 177 Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Lutetium 177 Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Lutetium 177 Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Technetium 99M Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Technetium 99M Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Technetium 99M Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 30. Global Kit Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Kit Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Kit Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Ready To Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Ready To Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Ready To Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 37. Global Diagnostic Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Diagnostic Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Diagnostic Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Cardiology Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Cardiology Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Cardiology Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Global Diagnostic Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Diagnostic Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Diagnostic Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Research Institute Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Research Institute Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Research Institute Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 72. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 73. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 74. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 75. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 76. North America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 79. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 80. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 81. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 83. Latin America Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 86. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 87. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 88. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 90. Europe Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 93. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 94. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 95. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 97. Middle East Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 100. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 101. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 102. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 103. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 104. Africa Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 108. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 109. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 110. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 111. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 112. ASEAN Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 115. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 116. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 117. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 118. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 119. GCC Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 122. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 123. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 124. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 125. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 126. European Union Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 129. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 130. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 131. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 133. BRICS Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 136. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 137. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 138. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 140. G7 Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 143. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 144. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 145. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 147. NATO Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 150. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 151. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 152. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 153. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 154. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 155. United States Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 157. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 158. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 159. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 160. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 162. Canada Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 164. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 165. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 166. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 167. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 169. Mexico Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 171. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 172. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 173. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 174. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 175. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 176. Brazil Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 178. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 179. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 180. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 181. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 182. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 183. United Kingdom Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 185. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 186. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 187. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 188. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 190. Germany Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 192. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 193. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 194. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 195. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 196. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 197. France Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 199. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 200. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 201. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 202. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 203. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 204. Russia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 206. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 207. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 208. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 209. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 211. Italy Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 213. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 214. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 215. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 216. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 218. Spain Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 220. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 221. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 222. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 223. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 224. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 225. China Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 227. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 228. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 229. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 230. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 231. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 232. India Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 234. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 235. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 236. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 237. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 238. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 239. Japan Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 241. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 242. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 243. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 244. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 245. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 246. Australia Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, 2017-2032 (USD Million)
TABLE 248. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Production Method, 2017-2032 (USD Million)
TABLE 249. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Isotope Type, 2017-2032 (USD Million)
TABLE 250. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Radiopharmaceutical Form, 2017-2032 (USD Million)
TABLE 251. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Application, 2017-2032 (USD Million)
TABLE 252. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by Diagnostic, 2017-2032 (USD Million)
TABLE 253. South Korea Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market Share, by Key Player, 2025
TABLE 255. Global Radioisotopes for Nuclear Medicine Diagnosis & Treatment Market, Key Experts

Companies Mentioned

  • Advanced Accelerator Applications S.A.
  • Australian Nuclear Science & Technology Organisation
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium Pharma SAS
  • Eckert & Ziegler AG
  • GE HealthCare Technologies, Inc.
  • IRE NV
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Radiopharma Pvt. Ltd.
  • Lantheus Medical Imaging, Inc.
  • Nordion Inc.
  • NorthStar Medical Radioisotopes LLC
  • NTP Radioisotopes Pvt. Ltd.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Nuclear Medicine Radioisotope - Global Strategic Business Report - Product Image

Nuclear Medicine Radioisotope - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Nuclear Medicine Radioisotopes Market Report 2026 - Product Image

Nuclear Medicine Radioisotopes Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Nuclear Medicine Radioisotopes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Nuclear Medicine Radioisotopes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.